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ARTICLE
Genetically stable poliovirus vectors activate
dendritic cells and prime antitumor CD8
T cell immunity
Mubeen M. Mosaheb1, Elena Y. Dobrikova2, Michael C. Brown2, Yuanfan Yang 3, Jana Cable1,
Hideho Okada4,5, Smita K. Nair6, Darell D. Bigner2, David M. Ashley2 & Matthias Gromeier1,2*
Viruses naturally engage innate immunity, induce antigen presentation, and mediate CD8 T
cell priming against foreign antigens. Polioviruses can provide a context optimal for
generating antigen-specific CD8 T cells, as they have natural tropism for dendritic cells,
preeminent inducers of CD8 T cell immunity; elicit Th1-promoting inflammation; and lack
interference with innate or adaptive immunity. However, notorious genetic instability and
underlying neuropathogenicity has hampered poliovirus-based vector applications. Here we
devised a strategy based on the polio:rhinovirus chimera PVSRIPO, devoid of viral neuro-
pathogenicity after intracerebral inoculation in human subjects, for stable expression of
exogenous antigens. PVSRIPO vectors infect, activate, and induce epitope presentation in
DCs in vitro; they recruit and activate DCs with Th1-dominant cytokine profiles at the
injection site in vivo. They efficiently prime tumor antigen-specific CD8 T cells in vivo, induce
CD8 T cell migration to the tumor site, delay tumor growth and enhance survival in murine
tumor models.
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Bolstering the potency or frequency of antitumor cytotoxic Tlymphocyte (CTL) responses has achieved durableresponses in cancer patients1–5. Generating such responses
in situ requires an appropriate costimulatory context coinciding
with presentation of target antigen by MHC class I. Viral vectors
offer a compelling approach to engage CTLs by providing
intracellular expression of both, pathogen-associated molecular
patterns and the desired antigen. This recapitulates the cues CTLs
have evolved to respond to upon intracellular pathogen infection;
in essence portraying the target antigen as a viral signature.
A clinically feasible poliovirus vector platform has remained
elusive, despite obvious advantages: tropism for antigen-
presenting cells6,7, a rapid lifecycle capable of propagating
vector-encoded antigen, no interference with immune activation
and antigen presentation, and robust engagement of inflamma-
tory responses. We report the engineering of genetically stable
vectors based on the highly attenuated PVSRIPO [type 1 polio-
virus (Sabin) live-attenuated vaccine containing a rhinovirus type
2 internal ribosomal entry site (IRES)]8. PVSRIPO has inherent
tropism for macrophages and DCs in primates6, and exhibits an
unusual phenotype in such cells, characterized by lingering,
sublethal infection and profound proinflammatory stimulation9.
PVSRIPO is devoid of neuropathogenicity, even after high-dose
intracerebral inoculation in non-human primates10 and in human
subjects with recurrent WHO grade IV malignant glioma (glio-
blastoma; GBM)11. Intratumoral delivery of PVSRIPO has
achieved clinical and radiographic responses with durable long-
term survival (>36 months) in 21% of patients with recurrent
GBM, an indication notorious for lacking immune engagement11.
Unlike the extremely heterogeneous adult malignant gliomas,
the predominantly pediatric Diffuse Midline Gliomas (DMG)
frequently are defined by a loss in histone 3 (H3K27)
trimethylation12,13. Approximately 80% of DMGs of the pons
[Diffuse Intrinsic Pontine Glioma (DIPG)] express H3.3K27M,
which also occurs in spinal and thalamic DMGs. In addition,
H3.3G34R/V is associated with hemispheric high grade
gliomas in pediatric patients12. Loss of H3K27 trimethylation
has been implicated in aberrant gene expression control and
tumorigenesis14.
H3.3K27M is a high affinity HLA-A2-restricted tumor neoan-
tigen and T cells bearing the H3.3K27M-specific TCR lysed
H3.3K27M-positive glioma cells in vitro and in vivo15. Devising
effective immunotherapies for DMG/DIPG is an urgent man-
date, as there is no standard treatment for this invariably fatal
disease with dismal prognosis. We describe a genetically stable
PVSRIPO-based vector platform to generate antitumor respon-
ses against the H3.3K27M epitope. We show that PVSRIPO-based
vectors target DCs to: elicit sublethal viral translation and pro-
pagation resulting in expression of foreign epitopes in a highly
adjuvated context; induce DC maturation markers; provoke type
I/III interferon (IFN) release; present the H3.3K27M epitope to
T cells; generate locoregional proinflammatory activation,
immune cell infiltration and DC activation in vivo; and trigger
DC migration to immunization site-draining lymph nodes
in vivo, where they express the H3.3K27M epitope. Vector
immunization induces CD8 T cell infiltration into tumors, and
exhibits significant anti-tumor efficacy in immunocompetent
rodent tumor models.
Results
Genetically stable PVSRIPO vectors. Among diverse proposals
for poliovirus-derived vectors, “polyprotein fusion” approaches
are most advanced16–20. Enterovirus+ strand RNA genomes
encode a single polyprotein, which is processed by two viral
proteases (2Apro, 3Cpro). For polyprotein fusion, foreign
polypeptides are N-terminally or internally fused to the poly-
protein and released via an engineered viral protease cleavage site
(Fig. 1a, b)16. Poliovirus polyprotein fusion vectors delivering
simian immunodeficiency virus (SIV)-derived polypeptides or the
ovalbumin (OVA) model antigen were tested in non-human
primates16–18 and in human CD155-transgenic (hCD155-tg)
mice20. Effective humoral, CD4- and CD8 T cell responses16–20
protected macaques against lethal SIV challenge18. Yet, this vector
design, where burdensome foreign sequences were simply added
to the viral genome, triggered rapid deletion events21. We rea-
soned that to achieve genetic stability, foreign inserts must be
functionally integrated into the genome, in order to contribute to
viral fitness. All enterovirus genomes contain a cryptic AUG at
the base of stem loop domain (SLD) VI of the IRES (Fig. 1a)22.
Placing the cryptic AUG into KOZAK context and deleting SLD
VI yields viable virus with growth deficits23,24. We used this
scenario to incentivize insert retention, by putting the cryptic
AUG into KOZAK context and replacing SLD VI with a coding
region for foreign polypeptides (Fig. 1b, g).
We constructed a vector for the OVA class I epitope
(SIINFEKL) along these guidelines (mOVA1; Fig. 1b), using a
mouse-adapted PVSRIPO variant (mRIPO)9 as backbone (to
enable proof-of-principle immunization tests in mice). We
assessed genetic stability through 20 serial passages in HeLa
cells. Corroborating earlier findings23, the OVA insert was
retained over 20 passages. A single nt adaption emerged in
passage 10: mixed C609/A that became A609 by passage 20
(Fig. 1d), suggesting a fitness advantage conveyed by A609.
C609A is a missense mutation (L/M; Fig. 1d) that does not affect
SIINFEKL epitope processing and presentation. Cloned mOVA2
carrying the A609 substitution remained genetically intact
through 20 serial passages in HeLa cells (Fig. 1e); mOVA2
formed larger plaques with enhanced growth compared to
mOVA1 (Fig. 1f).
A vector delivering the DMG/DIPG H3.3K27M epitope [RIPO
(H3.3); Fig. 1g] remained unchanged after 20 serial passages in
HeLa cells (Supplementary Fig. 1). RIPO(H3.3)’s plaque size
and growth kinetics were enhanced compared to PVSRIPO
with SLD VI deleted [RIPOδ6; Fig. 1h), suggesting that the
foreign insert conveys a fitness advantage. RIPO(H3.3) retained
the neuron-specific translation deficit of its PVSRIPO parent,
which defines neuroattenuation in vivo25,26. This was evident
as deficient RIPO(H3.3) growth in HEK293 cells (adrenal
precursor cells of neuroectodermal origin27) (Supplementary
Fig. 2). HEK293 cells accurately reflect the neuroattenuation
phenotypes of PVSRIPO and the poliovirus (Sabin)
vaccines28,29. The PVSRIPO platform can be flexibly adapted
to accommodate diverse inserts; we derived genetically stable
vectors expressing peptides encoding the isocitrate dehydro-
genase 2 (IDH2) R172G mutation, or SIV p55 Gag-derived
peptides (Supplementary Fig. 3).
mOVA2 initiates translation from the intended AUG. The
C609A substitution in mOVA2 resulted in tandem, in-frame
AUGs separated by 18nt; both of these were in ideal KOZAK
context (A/G . . AUG G) (Supplementary Fig. 4a). RIPO(H3.3)
inherently contains tandem, in-frame AUGs (separated by 36nt);
the downstream AUG, however, is in poor KOZAK context (C . .
AUG A) (Fig. 1g). mOVA2 acquiring a new in-frame AUG in
optimal KOZAK context raises questions about initiation codon
usage in our vector design, as usage of a downstream AUG would
truncate the foreign coding region. To examine initiation codon
usage in our vectors, we used mOVA2 variants with the upstream
AUG in poor KOZAK context and/or a frameshift in-between the
two tandem AUGs. These tests showed that the intended
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13939-z
2 NATURE COMMUNICATIONS |          (2020) 11:524 | https://doi.org/10.1038/s41467-019-13939-z | www.nature.com/naturecommunications
initiation AUG at nt 588 in optimal KOZAK context is preferred
(Supplementary Fig. 4).
mOVA2 and RIPO(H3.3) express and process foreign epitopes.
With our vector design, the H3.3K27M/OVA epitopes are fused to
the viral P1 or VP0 precursors and processed by 2Apro cleavage
(Fig. 2a). An H3.3K27M-specific antibody probe detected such
H3.3K27M-fusion polypeptides in RIPO(H3.3)-infected HeLa cells
(Fig. 2b). These appeared early (H3.3K27M-P1 peaked at 3hpi)
and declined thereafter, presumably due to viral proteolytic
processing. Processing of the H3.3K27M-VP0 fusion product was
delayed compared to H3.3K27M-P1, in line with the poliovirus
processing sequence (Fig. 2b)30. See Supplementary Fig. 5 for
viral fusion-polypeptide expression analyses in mOVA2-infected
HeLa cells. Expression of viral H3.3K27M/OVA-fusion proteins
with our vector design corroborates our studies of initiation
codon usage (Supplementary Fig. 4).
Sublethal infection of hCD155-tg mouse BMDCs with mOVA2.
Monocytes, macrophages, and DCs express the poliovirus receptor
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CD15531 and are natural, high priority poliovirus targets in pri-
mates6. Accordingly, poliovirus infects monocytes, macrophages,
and DCs in vitro7,31,32. In line with productive infection in primate
CD11c+ macrophages/DCs in vivo6, poliovirus infection yields
cytopathogenic virus replication and host protein synthesis shut-off
in human DCs derived from PBMCs7. In contrast, PVSRIPO
exhibits a sublethal phenotype in human DCs9, with protracted,
low-level viral translation and propagation, accompanied by sus-
tained, potent type I-dominant IFN activation9.
We tested mOVA2-infected DCs for: viral translation
and cytotoxicity; proinflammatory cytokine production;
expression and presentation of OVA class I epitope; and
antigen-specific activation of CD8+ cytotoxic T cells. To this
end, we established bone marrow-derived DC (BMDC) cultures
from hCD155-tg mice either differentiated with GMCSF/IL4
(GMCSF-BMDCs; Fig. 3a) or with Fms-related tyrosine kinase 3
ligand (FLT3L-BMDCs; Fig. 3b). The latter consist of a mixture
of CD8α+ (Batf3+ DCs) and CD8α− DCs33,34; CD8α+
DCs have a prominent role in eliciting CTL responses35,36.
GMCSF− (Fig. 3a) or FLT3L− (Fig. 3b) BMDCs were
either mock-infected, or infected with mOVA2 at a multiplicity
of infection (MOI) of 10. As a positive control for proin-
flammatory stimulation, we used lipopolysaccharide (LPS)
(Fig. 3a, b).
mOVA2 infection of GMCSF- and FLT3L-BMDCs revealed
the absence of eIF4G1 cleavage, the hallmark of poliovirus
cytopathogenicity37. We did not detect productive viral transla-
tion, i.e. viral 2C/2BC, in GMCSF-BMDCs (Fig. 3a). In contrast,
viral protein synthesis was abundant in FLT3L-BMDCs (Fig. 3b).
Viral translation peaked early (12hpi) and gradually declined
without evidence for cytopathogenicity (i.e. eIF4G1 cleavage),
indicating an ability of the FLT3L-BMDCs to prevent cytotoxic
damage stemming from viral translation (Fig. 3b).
mOVA2-induced type I IFN-dominant activation of mouse
BMDCs. Both, GMCSF- and FLT3L-BMDCs responded to
mOVA2 infection with type I IFN activation signatures, e.g.
induction of p-STAT1(Y701), STAT1, TAP1 and ISG15 (Fig. 3a,
b). This response was delayed in FLT3L- relative to GMCSF-
BMDCs, especially at 12hpi (compare mOVA2-infected to LPS-
treated cultures; Fig. 3a, b). Results of repeat assays are shown in
Supplementary Fig. 6a, b. mOVA2 infection led to the upregu-
lation of DC maturation markers (CD40/80/86) and PD-L1 in a
pattern that was qualitatively similar, but quantitatively diverging
in FLT3L- vs. GMCSF-BMDCs (Fig. 3a, b). Levels of MHC I and
-II remained unchanged in mOVA2-infected GMCSF- and
FLT3L-BMDCs throughout the assay (Supplementary Fig. 6a, b).
Delayed type I IFN responses in FLT3L-BMDCs were also evident
Fig. 1 PVSRIPO-based polyprotein fusion vectors with IRES SLD VI replacement. a An engineered type 1 IRES with the conserved, cryptic AUG initiating a
foreign ORF mimicking the predicted overall structure of the HRV IRES SLD VI (orange). The approximate ‘footprint’ of eIF4G in type 1 IRESs62,63,
anchoring the eIF4G:4A:4B translation initiation helicase, is indicated. b Genetic structure of mOVA1, expressing a VSGLEQLESIINFEKLTEWTSSNVM
polypeptide, flanked by a (viral) N-terminal MGAQ sequence and a C-terminal engineered cleavage site (KGLTTY^G) for poliovirus 2Apro (blue letters).
Salient vector design principles are indicated: [1] convert the cognate cryptic AUG into the initiation AUG; [2] replace SLD VI with an epitope-encoding
sequence mimicking SLD VI; [3] engineer a 2Apro cleavage site for epitope release. c, d Sequence of the mOVA1 insert (nt 600-657) at passages 3, 10 and
20: a C-to-A substitution at nt 609 emerging in passage 10 (c circled) gives rise to a Leu-to-Met coding change in mOVA2 (d). e Sequence chromatogram
of mOVA2 (nt 600-657) at passages 3, 10 and 20. f Plaque phenotypes (left panel), one-step growth curves in HeLa cells (middle panel) and translation
kinetics in HeLa cells (right panel) of mOVA1 and 2. g Genetic structure of RIPO(H3.3) expressing a KQLATKAARM*SAPSTGGVKKPHR polypeptide
derived of histone 3.3; the Lys-to-Met substitution at aa27 is indicated in red. The previously defined neoepitope in mutant H3.3K27M15 is indicated by
asterisks. h Plaque phenotypes (left panel) and one-step growth curves in HeLa cells (right panel) of RIPOδ6 and RIPO(H3.3). f, h n= 3 independent
samples for 0–12hpi; error bars denote Standard Error of the Mean (SEM).
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in cytokine release assays in mOVA2-infected GMCSF- (Fig. 3c)
and FLT3L-BMDCs (Fig. 3d). In both, GMCSF- and FLT3L-
BMDCs, substantial responses were recorded for type 1 IFNs
(IFNα/β), CCL5 (RANTES) and CXCL10 (Fig. 3c, d) (other tested
cytokines had low or absent responses; Supplementary Fig. 7a, b).
While proinflammatory cytokine responses in FLT3L-BMDCs
were delayed, their amplitude was higher compared to GMCSF-
BMDCs (Fig. 3c, d). Collectively, these findings suggest that
mOVA2 infection of BMDCs stimulated their antigen-presenting
and T cell co-stimulation capacity.
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mOVA2-infected BMDCs present SIINFEKL epitope. To test if
mOVA2-infected and activated DCs present the SIINFEKL epi-
tope and stimulate T cell function, we infected GMCSF-BMDCs
with mOVA2 (MOI 10) and co-cultured them with either OT-I
(SIINFEKL-specific) or naïve CD8+ T cells. We compared IFN-γ
and granzyme B production by mOVA2-infected- to unstimu-
lated-, SIINFEKL peptide-, LPS-, LPS+ SIINFEKL−, mRIPO-
or mRIPO+ SIINFEKL-stimulated GMCSF-BMDCs (Fig. 3e).
mOVA2 infection alone mirrored the response to LPS+ SIIN-
FEKL-stimulation (Fig. 3e). mRIPO was devoid of activity in this
assay, but mRIPO+ SIINFEKL-stimulation instigated responses
that exceeded those to SIINFEKL-stimulation alone (Fig. 3e).
These observations indicate expression, processing, and pre-
sentation of foreign polypeptides by PVSRIPO-based vectors in
DCs, and illustrate the costimulatory potential of PVSRIPO-based
vector infection.
Adjuvant effects of mOVA2 in vivo. A salient argument for viral
vector-delivery of antigens is local adjuvancy from the stimuli
provided by virus challenge. To test this, we immunized hCD155-
tg mice with either mOVA2 or DMEM (Mock) by the intra-
muscular (i.m.) route and isolated skeletal muscle tissue from the
inoculation site to assess the presence of mOVA2 by plaque assay;
isolated skeletal muscle tissue from the inoculation site (24hpi)
for tests of cytokine responses (Fig. 4a; compare to in vitro
BMDC infection in Fig. 3c, d; Supplementary Fig. 7); assessed
local immune cell infiltrates by flow cytometry (Fig. 4b); and
tested DC maturation status by evaluating CD40 and CD86
expression on local infiltrating DCs (Fig. 4c).
A breadth of cytokines was induced by mOVA2 infection
in vivo (Fig. 4a). The four principal responses to mOVA2
infection of DCs in vitro, IFNα/β, CCL5, CXCL10 (Fig. 3c, d), and
IFNγ evident in the OT-I assay (Fig. 3e), also occurred in vivo
(Fig. 4a). As suggested by the pattern of the local cytokine/
chemokine signature, there was profuse recruitment of immune
cells, e.g. DCs, macrophages and T cells, to the site of
immunization (Fig. 4b). Confirming data with in vitro infection
of BMDCs with mOVA2 (Fig. 3a, b), local DCs acquired
maturation markers (CD40 and CD86), with CD40 being the
most responsive (Fig. 4c).
Locoregional inflammation elicited by i.m. mRIPO-vector
administration, immune cell infiltration, and costimulatory DC
activation indicated that local DC infection with vector,
and (infected) DC migration to draining lymph nodes may
occur in vivo. Therefore, we examined antigen expression in
(popliteal) lymph nodes draining the vector inoculation site
in vivo. To this end, we used the mouse-adapted form of RIPO
(H3.3) [mRIPO(H3.3)] for i.m. immunization of hCD155-tg
mice, because a suitable antibody for immunohistochemistry
(IHC) of the H3.3K27M epitope is available. H3.3K27M IHC
revealed that mRIPO(H3.3) had drained to popliteal lymph
nodes in H3.3K27M-expressing cells, possibly migrated mRIPO
(H3.3)-infected DCs (Fig. 4d).
As reported previously for wt poliovirus after i.m. inocula-
tion in hCD155-tg mice38, the extent of mRIPO(H3.3)
propagation in skeletal muscle at the inoculation site was very
modest (Supplementary Fig. 12). Sequencing of mRIPO(H3.3)
virus isolated from skeletal muscle tissue at the immunization
site (at day 4 after i.m. immunization) revealed that the foreign
insert remained genetically intact (Supplementary Fig. 13). This
corroborated our data on genetic stability during in vitro
passaging (Supplementary Fig. 1).
Vector immunization primes CD8 T cells in vivo. We investi-
gated mOVA2′s capacity for generating antigen-specific CD8 T
cell responses in vivo. hCD155-tg mice were primed on day 0 and
boosted on day 14 with mRIPOδ6 (empty vector), poly(I:C), poly
(I:C)+ SIINFEKL peptide, mRIPOδ6+ SIINFEKL or mOVA2 by
i.m. inoculation. SIINFEKL-specific CD8 T cell responses were
monitored by IFN-γ ELISPOT with splenocytes (Fig. 5a, b) and
pentamer staining of peripheral blood (Fig. 5c, d). Both assays
revealed mOVA2-generated SIINFEKL-specific CD8 T cell
responses in vivo (Fig. 5a, d). Regimens lacking the antigen
[mRIPOδ6, poly(I:C)] did not yield responses. The response to
mOVA2 immunization was consistently superior to poly(I:C)+
SIINFEKL or mRIPOδ6+ SIINFEKL both by ELISPOT and
pentamer staining (Fig. 5a, d). This suggests that the range of
adjuvancy provided by the vector; and vector-mediated expres-
sion of the epitope inside vector-activated cells contribute to an
efficient effector immune response in vivo. If mOVA2′s capacity
for eliciting SIINFEKL-specific CD8 T cell responses is due to
infection of-, epitope expression in-, and costimulatory activation
of DCs, then adoptive transfer of wt C57Bl6 mice (which do not
support poliovirus infection) with ex vivo mOVA2-infected
syngeneic FLT3L BMDCs from hCD155-tg mice should have a
similar effect. This was indeed the case (Supplementary Fig. 16).
We also tested the capacity of mRIPO(H3.3) to elicit
H3.3K27M-specific CD8 T cell responses in vivo. We first
generated a suitable mouse host, since the H3.3K27M epitope is
HLA-A2 restricted15. The offspring of crossing (homozygous)
hCD155-tg mice with (homozygous) AAD-tg C57Bl6 mice39
(see below) was used for mRIPO(H3.3) immunization as
described for mOVA2 above. For controls, we immunized litter
mates with Complete Freud’s Adjuvant (CFA) and H3.3K27M
peptide (RMSAPSTGGV) emulsion (Fig. 5e, f). Staining of
peripheral blood performed with a HLA-A2-H3.3K27M tetramer
demonstrated that immunization with mRIPO(H3.3) generated
H3.3K27M specific CD8 T cells (Fig. 5e, f).
Anti-tumor efficacy of mOVA2 Immunization. We first
evaluated our PVSRIPO vectors in a standard, spontaneous, and
relatively ‘non-immune engaged’40 immunocompetent mouse
tumor model, B16F10.9-OVA melanoma. The OVA class I epitope
SIINFEKL strongly binds to H2Kb in C57Bl6 mice, permitting
evaluation of mOVA2 without MHC mismatch problems.
Fig. 3 mOVA2 activates DCs and mediates SIINFEKL epitope presentation to CD8 T cells. a, b Immunoblot and flow cytometry analysis of GMCSF- (a)
and FLT3L- (b) BMDCs showing type I IFN-dominant activation and upregulation of costimulatory molecules upon infection with mOVA2. For co-
stimulatory molecule expression, asterisks denote statistically significant differences from mock (0 h)-treated samples as determined by Two-way RM-
ANOVA protected Dunnett’s post hoc test; (a) n= 4; (b) n= 3. Repeat immunoblot assays and gating strategy are shown in Supplementary Fig. 6a–c,
respectively. c, d Multiplex ELISA showing cytokine profiles of infected GMCSF- (c) and FLT3L- (d) BMDCs. Asterisks denote statistically significant
differences from mock (0 h)-treated samples determined by One-way ANOVA protected Dunnett’s post hoc test; n= 3. e GMCSF-BMDC/OT-I co-culture
assays. Asterisks denote statistically significant differences determined by Two-way ANOVA protected Sidak’s multiple comparison test, n= 3. The assay
was performed three times; representative results are shown. a–e Error bars denote SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n= number of
independent replicates.
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Therefore, to assess if mOVA2-instigated CD8 T cell responses
exert anti-tumor efficacy, we challenged the B16F10.9-OVA
tumor model in hCD155-tg mice. In mOVA2-immunized mice,
tumor progress was significantly slowed with a significant survival
benefit compared to mRIPOδ6-immunized mice (Fig. 6a, b). To
mechanistically correlate these findings with mOVA2′s capacity
to induce tumor antigen-specific CD8 T cell responses (Fig. 5a–d),
we studied B16F10.9-OVA tumor immune infiltrates (Fig. 6c).
This is not feasible with the approach described for Fig. 6a, b,
because the mOVA2-induced treatment effect reduced tumor
size at the testing interval (day 11), preventing comparison of
mRIPOδ6- vs. mOVA2-immunized animals in similarly sized
tumors (Fig. 6a). Therefore, B16F10.9-OVA tumors were
implanted (day 0) followed by i.m. immunization with mRIPOδ6
or mOVA2 (day 1) and tumors were isolated at day 11 for analyses
of CD8 and CD4 T cell infiltration by flow cytometry (Fig. 6c;
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Fig. 4 Intramuscular immunization with PVSRIPO vectors induced locoregional inflammation. a Cytokine induction profile in gastrocnemius muscle 12 h
post i.m. immunization with mOVA2 (n= 9) or DMEM (Mock; n= 8). b Immune infiltrates in treated muscle 24 h post immunization with mOVA2 (n= 9)
or DMEM (Mock; n= 9). c Upregulation of costimulatory molecules on muscle-infiltrating DCs upon immunization mOVA2 (n= 10) or DMEM (Mock;
n= 10). b, c Representative gating is shown in Supplementary Figs. 8, 9. d Immunohistochemistry of the H3.3K27M epitope in a popliteal lymph node
draining the mRIPO(H3.3) inoculation site. H3.3K27M positive cells, presumably antigen-presenting cells infected with mRIPO(H3.3), are observed.
H3.3K27M staining in sections from lymph nodes of a mock-immunized animal, and isotype-matched negative control staining of sections from the same
lymph node are shown in Supplementary Figs. 10, 11, respectively. a–c Experiments were repeated twice, representative results are shown. Asterisks denote
statistical significance determined by two-tailed student’s t test. Error bars denote SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n= number of
independent animals.
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Supplementary Fig. 17). mOVA2-immunized mice had signifi-
cantly higher T cell (CD3+) infiltration in the tumor,
when compared to mRIPOδ6-immunized mice (Fig. 6c). Also,
the CD8:CD4 T cell ratio was significantly skewed towards CD8
T cells in mOVA2-immunized mice (Fig. 6c). This suggests that
SIINFEKL-specific CD8 T cells generated by mOVA2 immuniza-
tion migrate to and infiltrate the tumor and mediate the decrease in
tumor burden.
Next, we assessed if the therapy effect of mOVA2 immunization:
correlates with the enhanced frequency of SIINFEKL-specific CD8
T cells [compared to poly(I:C)+ SIINFEKL; Fig. 5a–c]; and
depends on the presence of the OVA antigen in the tumor target.
To this end, hCD155-tg mice were immunized with mRIPOδ6 or
mOVA2 or with poly(I:C) or poly(I:C)+ SIINFEKL peptide by i.
m. inoculation (as described for Fig. 5a–c). Immunized mice
received bilateral tumor implants: ipsilateral B16F10.9-OVA and
contralateral B16F10.9 (Fig. 6d). None of the immunization
regimens altered the progression of B16F10.9 tumors, lacking
OVA (Fig. 6d). Only mOVA2 immunization prevented growth of
the ipsilateral B16F10.9-OVA tumors (Fig. 6d, e). Thus, the
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Fig. 5 mOVA2 and mRIPO(H3.3) induced epitope-specific CD8 T cell responses in vivo. a, b IFN-γ ELISPOT showing generation of SIINFEKL-specific
CD8 T cells upon i.m. immunization of hCD155-tg mice with mOVA2. Cells were either left unstimulated or stimulated with peptide (SIINFEKL or MOG
negative control); Concanavalin A stimulation (positive control) is shown in Supplementary Fig. 14. c, d H2Kb-SIINFEKL pentamer staining of peripheral
blood, gated on CD11b−CD19− cells, showing % CD8 T cells that are SIINFEKL-specific. e, f HLA-A2-RMSAPSTGGV tetramer staining of peripheral
blood, gated as in (c, d), showing % CD8 T cells that are RMSAPSTGGV-specific upon i.m. immunization of AAD_hCD155-tg mice with Complete
Freund’s Adjuvant (CFA) and RMSAPSTGGV peptide emulsion, or with mRIPO(H3.3). c, f The gating strategy employed is shown in Supplementary Fig. 15.
a, d, e Asterisks denote statistical significance between groups determined by RM-ANOVA protected Tukey’s- (a) or 1-way ANOVA protected Sidak’s post
hoc test (d, e). All experiments were performed twice and representative results are shown. Error bars denote SEM. a mRIPOδ6 (n= 9), poly(I:C) (n= 3),
poly(I:C)+ SIINFEKL (n= 9), mRIPOδ6+ SIINFEKL (n= 9), mOVA2 (n= 10). d mRIPOδ6 (n= 9), poly(I:C) (n= 3), poly(I:C)+ SIINFEKL (n= 10),
mRIPOδ6+ SIINFEKL (n= 10), mOVA2 (n= 9). e mRIPOδ6 (n= 3), CFA+ RMSAPSTGGV (n= 2), mRIPO(H3.3) (n= 3); n= number of mice. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.
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Fig. 6 mOVA2 immunization delays tumor growth and induces tumor CD8 T cell infiltration. a Mice were immunized with either mOVA2 or mRIPOδ6
on day 0, boosted on day 14, B16F10.9-OVA cells were implanted subcutaneously 3 weeks later, and tumor volumes were monitored (mice were
euthanized when tumors reached 1000mm3). mOVA2-immunized mice survived significantly longer than mRIPOδ6 treated animals [P= 0.0017, Log-rank
(Mantel-Cox) test, n= 10]. A repeat assay including a mock-immunized group is shown in Supplementary Fig. 18. (b) Tumor progression in individual mice
from experiment in (a). c B16F10.9-OVA tumors from mOVA2-immunized mice had elevated CD8 T cell infiltration compared to mRIPOδ6-immunized
mice. The gating strategy is shown in Supplementary Fig. 17. Two-tailed t-test, n= 4. *P < 0.05, **P < 0.01. d The anti-tumor effect of mOVA2
immunization correlates with SIINFEKL CD8 T cell frequency and is specific to tumors expressing OVA. Mice were immunized with mRIPOδ6, mOVA2,
poly(I:C), or poly(I:C)+ SIINFEKL as in Fig. 5a, followed by bilateral B16F10.9 and B16F10.9-OVA tumor implantation as shown (left panel). Tumor
progression was monitored until reaching >1000mm3 in the first test animal (asterisks; this occurred in the contralateral B16F10.9 tumors in all treatment
groups). mRIPOδ6 n= 9, mOVA2 n= 8, poly(I:C)+ SIINFEKL n= 8, poly(I:C) n= 10. All error bars represent SEM; n= number of animals.
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antitumor effect of mOVA2 immunization is due to its capacity to
instigate CD8 T cell responses against a tumor-specific antigen, as
evident in ELISPOT and pentamer analyses (Fig. 5a–c).
mRIPO(H3.3) enhances survival in a mouse glioma model. We
evaluated mRIPO(H3.3) immunization in an immunocompetent
malignant glioma model transduced with HLA-A2 (AAD) and the
H3.3K27M variant (the gene products of mouse and human H3F3A
are 100% conserved) (Fig. 7a, b). Of the available syngeneic mouse
glioma models, we favor the 20-methylcholanthrene-induced
CT2A41, because it recapitulates the notorious aggressive
growth and immunotherapy resistance of the human disease42.
CT2A_AADH3.3K27M tumors were orthotopically implanted in
AAD_hCD155-tg mice (Fig. 7c, d).
I.m. immunization with mRIPO(H3.3) significantly extended the
survival of CT2A_AADH3.3K27M tumor-bearing mice when com-
pared to mRIPOδ6 immunized mice (Fig. 7e), in a manner similar
to mOVA2 immunization against B16F10.9-OVA (Fig. 6a). In a
repeat experiment, mRIPOδ6/mRIPO(H3.3)-immunized animals
received intraperitoneal inoculations of anti-CD8 antibodies for
CD8 T cell depletion (initiated 7 days prior to tumor implantation).
This abolished the therapeutic effect of mRIPO(H3.3) immuniza-
tion (Fig. 7f). Thus, PVSRIPO vector-induced H3.3K27M-specific
CD8 T cell responses successfully target intracerebral H3.3K27M+
malignant gliomas in vivo.
RIPO(H3.3)-induces type I IFN activation of human DCs. We
evaluated RIPO(H3.3) in primary human DCs to validate the
vector phenotype, and to test presentation of the H3.3K27M
antigen to T cells. Infection of human monocyte-derived DCs
(from HLA-A2 donors) with RIPO(H3.3) (Fig. 8a; repeat analyses
are shown in Supplementary Fig. 20a) did not elicit a cyto-
pathogenic program, consistent with the mouse BMDC analyses
of mOVA2 (Fig. 3a, b). RIPO(H3.3) translation in human DCs
was more efficient than mOVA2 in murine GMCSF-BMDCs,
likely reflecting host-specificity (Fig. 8a; compare Fig. 3a). RIPO
(H3.3) translation in human DCs closely tracked viral propaga-
tion, established in one-step growth curve assays (Fig. 8b). Viral
propagation was productive, if limited, with a ~10-fold surge in
virus progeny upon initial infection to reach a maximum of ~0.05
pfu per cell by 24hpi (Fig. 8b). Restricted RIPO(H3.3) propaga-
tion in human DCs is consistent with lacking cytopathogenicity9.
Increases in viral progeny were detected up to ~36hpi (Fig. 8b).
RIPO(H3.3)-infected human DCs exhibited IFN-dominant
proinflammatory activation and maturation (Fig. 8a, c, d) with
sustained type I IFN signatures, e.g. p-STAT1(Y701) and STAT1/
ISG15 induction (Fig. 8a). RIPO(H3.3) infection had similar
effects on DC maturation (CD40, −80/86, CCR7) and PD-L1 in
human DCs as mOVA2 in mouse BMDCs; however, the effect
was more pronounced in PVSRIPO’s natural human host (Fig. 8c;
compare Fig. 3a, b). RIPO(H3.3) did not affect MHC I/II surface
expression in human DCs, as in murine BMDCs (Supplementary
Figs. 6a, b; 20b).
Consistent with immunoblot analyses in human DCs (Fig. 8a),
and the cytokine response in mOVA2-infected BMDCs (Fig. 3c,
d), RIPO(H3.3) infection of human DCs induced a potent type I
(IFN-α/ß) and III (IFN-λ1) IFN-dominant response (Fig. 8d;
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Fig. 7 mRIPO(H3.3) immunization extends survival in an intracerebral glioma model. a, b CT2A cells were transduced with HLA-A2 (AAD) (a) and full-
length mouse histone 3.3(K27M) (b). DIPG 36 is a human H3.3K27M+DIPG cell line used as a positive control. c, d AAD_hCD155 transgenic mice express
HLA-A2 (AAD) in splenocytes (c) and hCD155 (in brain; d). HeLa cells were used as a positive control (the differences in hCD155 electrophoretic mobility
are due to differential glycosylation). e AAD_hCD155 transgenic mice were immunized by i.m. inoculation (day 1), implanted with CT2A_AADH3.3K27M
cells for orthotopic tumor initiation (day 7), boosted with the same regimen (day 14), and followed for assessment of weight and neurological status. Mice
were euthanized after losing 15% of their max. weight. mRIPO(H3.3)-immunized mice survived significantly longer than their mRIPOδ6-immunized
littermates [P= 0.0121, Log-rank (Mantel-Cox) test; mRIPOδ6 n= 9 animals, mRIPO(H3.3) n= 10]. A replicate is shown in Supplementary Fig. 19. (f) CD8
depletion abrogates the anti-tumor effect of mRIPO(H3.3) immunization. The assay was performed as in (e), with CD8 depletion antibody administered
every 4 days starting at 7 days prior to tumor implantation [P= 0.3493, Log-rank (Mantel-Cox) test; mRIPOδ6+ αCD8 n= 10 animals; mRIPO(H3.3)+
αCD8 n= 11].
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Fig. 8 RIPO(H3.3) activates human DCs and mediates H3.3K27M presentation to CD8 T cells. a Immunoblot of primary human DCs treated with poly(I:
C) or cGAMP or infected with RIPO(H3.3). b One-step growth curve showing virus replication in primary human DCs (n= 2); the experiment was repeated
twice and a representative series is shown. c Surface co-stimulatory molecule expression on DCs after infection. The gating strategy is shown in
Supplementary Fig. 20c. Asterisks depicts significant difference from Mock group as determined by Two-way RM-ANOVA protected Dunnett’s post hoc
test; 0–36 hpi n= 4, 48 hpi n= 3. d Cytokine induction profile in RIPO(H3.3) infected DCs. Asterisks denote significant difference from Mock 0 group as
determined by one-way ANOVA protected Dunnett’s post hoc test; n= 3. (e) Illustration of activation of DCs and antigen presentation to CD8 T cells.
f Primary DC and Jurkat-TCR co-culture showing RIPO(H3.3)-infected DCs can present the H3.3K27M antigen to CD8 T cells. Asterisks denotes significant
difference between groups as determined by one-way ANOVA protected Tukey’s post hoc test, n= 3 independent repeats. Experiment was repeated
twice. All error bars denote SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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IFN-λ1 was not part of the mouse panel). Compared to mouse
BMDCs, RIPO(H3.3)-infected human DCs exhibited a broader
proinflammatory response, including IL-6, IL-12, TNF-α, and
IFNγ (Fig. 8d). See Supplementary Fig. 21 for complete analyses.
RIPO(H3.3)-infected DCs present H3.3K27M to CD8 T cells.
Events stemming from RIPO(H3.3)-infection of human DCs
indicate broad type I/III IFN-dominant engagement, DC
maturation/antigen presentation enhancement, and T cell
recruitment and co-stimulation (Fig. 8e). To confirm RIPO
(H3.3)-mediated H3.3K27M epitope expression in human DCs
and its presentation to CD8 T cells, we used a Jurkat T cell clone
expressing CD8 and a H3.3K27M-specific TCR15 (Fig. 8e). Human
DCs were left unstimulated, treated with the H3.3K27M peptide,
infected with RIPOδ6, or infected with RIPO(H3.3) and co-
cultured with the H3.3K27M-TCR+, CD8+ Jurkat cells (J76CD8
+TCR+) (Fig. 8f). Robust IL-2 release by co-cultured J76CD8
+TCR+ only occurred with RIPO(H3.3) infection (Fig. 8f). IL-2
production after DC stimulation with the H3.3K27M peptide was
greatly stimulated by adding phorbol ester (TPA) to the culture;
in contrast, RIPO(H3.3) infection yielded similar levels of J76CD8
+TCR+ activation without TPA (Fig. 8f). Our data summarized
in Fig. 8e show that RIPO(H3.3) infects human DCs and provides
the 3 required signals for generating antitumor CD8 T cells, i.e.
MHC:epitope complexes; maturation marker induction; and
proinflammatory cytokines.
Discussion
Failure of early cancer vaccines—usually short peptides—were
attributed to lacking DC engagement43. Above all, peptide vac-
cination without proper DC costimulation and proinflammatory
cytokines can induce tolerance or T cell anergy44–46.
We show that pharmacokinetic problems of peptide vaccina-
tion, e.g. poor uptake/presentation by DCs43, are resolved with
PVSRIPO vectors. Due to poliovirus’ tropism for CD11c+
antigen-presenting cells6, PVSRIPO vectors naturally target them
for infection. RIPO(H3.3)-vectored epitope expression eliminates
the need for specialized antigen cross-presenting cells such as
CD141+ (BDCA3+) DCs, required with peptide approaches47.
Rather, in RIPO(H3.3)-infected DCs, the epitope is loaded onto
MHC class I through the classical pathway.
To stimulate DCs in cancer vaccine regimens, many synthetic
adjuvants have been enlisted. Yet, these agents incite broad,
indiscriminate stimulation, potentially out-of-sync with the
kinetics and distribution of epitope presentation. With RIPO
(H3.3), type I/III-dominant IFN release and costimulatory acti-
vation occur in the very cells expressing the H3.3K27M signature,
in step with lingering viral RNA replication. The importance of
coincident epitope expression and costimulatory activation in
DCs is evident in our studies: CD8 T cell responses to ‘empty’
mRIPOδ6 (providing the same adjuvancy as mOVA2) combined
with SIINFEKL peptide were far inferior to mOVA2.
Type I-dominant IFN responses, elicited by RIPO(H3.3)
infection of DCs, provide a fitting costimulatory context for the
induction of CD8 T cell responses48–52. Protracted, sublethal viral
propagation in DCs produced robust, sustained proinflammatory
cytokine release, in step with co-stimulatory molecule upregula-
tion and epitope expression. These events are crucial for CD8 T
cell priming53.
PVSRIPO’s DC-stimulating phenotype starkly contrasts with
the immune evasion and suppression programs of many human
pathogenic viruses, which coalesce on DCs and target MHC I
functions54. Picornaviruses, small RNA viruses with extreme
genetic austerity, lack the capacity to interfere with host adaptive
immunity. Thus, unlike most human viral pathogens, PVSRIPO
does not interfere with MHC I expression, antigen loading or
-presentation.
Tumor antigens often resemble self-antigens and are prone to
tolerance. The host innate response to picornavirus/PVSRIPO
infection is coordinated by the Melanoma-Differentiation
Associated Protein 5 (MDA5) pattern recognition receptor55.
Activation of MDA5 (e.g. by endogenous RNA) has been linked
to breaches of self-tolerance and autoimmunity56. Thus, MDA5-
mediated inflammation may be particularly apt to instigate CD8
T cell responses against weak tumor antigens.
PVSRIPO vectors elicit tumor antigen-specific CTLs capable of
infiltrating distant tumors, reduce tumor burden and significantly
increase survival in immunocompetent mouse tumor models. The
vector ‘IRES cassette’ accommodates any insert, provided that the
salient design principles of our approach are considered. Thus, we
outline a clinically feasible enterovirus vector approach based on
PVSRIPO that has a clinical track record of safe administration,
has empirical evidence for genetic stability, and is capable
of unique proinflammatory engagement of DCs for priming of
CD8 T cells.
Methods
Vector cloning, serial passage, one-step growth curves. See Supplementary
Table 1 for primers. To generate mOVA1, −2 and RIPO(H3.3), the foreign insert
was PCR synthesized with primers mOVA1/2-5′ and mOVA1-3′ or RIPO(H3.3)-
5′/3′, respectively. A corresponding IRES fragment, spanning from the PmlI site in
the cloverleaf of mRIPO (mRIPOδ6, mOVA1/2)9 or PVSRIPO [RIPO(H3.3)] to
the conserved cryptic AUG was generated with primers IRES-5′/3′. The mOVA2-
flag insert was generated as described above, with the mOVA2-flag-5′ primer
instead of mOVA2-5′. mOVA2s carrying an upstream AUG in poor Kozak con-
text, or a frameshift in the foreign insert, were generated as described above with
primers mOVA2-PC-5′ or mOVA2-FS-5′ substituting for mOVA2-5′, respectively,
and primer mOVA2-PC-3′ replacing IRES-3′ for the former. Fusion PCR with the
foreign insert+ IRES fragment as templates using flanking primers IRES-5′/
mOVA1-3′ (mOVA1/2 and derivates) or IRES-5′/RIPO(H3.3)-3′ [RIPO(H3.3)]
yielded segments encompassing the IRESs/foreign inserts for mOVA1/2 and RIPO
(H3.3). mRIPOδ6 was generated using IRES-5′ and IRESδ6-3′ and the mRIPO
IRES as template. These were inserted into the full-length cDNA clone of PVSRIPO
digested with PmlI-SacII (mRIPOδ6, mOVA1/2 and derivates) or EcoRI-SacI
[RIPOH3.3)]. In vitro synthesis of infectious RNA was performed using MEGA-
script T7 (Thermo, AM1334) for deriving vectors23,24. For serial passage, 3 × 106
HeLa cells in 60 mm dishes were infected with vector (MOI 1; 24 h), freeze-thawed,
the resulting lysate centrifuged to pellet debris, and 100 μl of the supernatant used
to infect another HeLa cell culture (MOI of ~1). This procedure was repeated 20
times. Total RNA from infected cells at passages 3, 10, and 20 was isolated using
TRIzol (ThermoFisher), reverse transcription was performed using Superscript IV
(ThermoFisher) with primer Seq-3′, and the region encompassing the entire IRES,
sequences coding for the foreign epitope and the adjoining viral polyprotein were
PCR-amplified from cDNA with primers IRES-5′ and Seq-3′ for sequencing. One-
step growth curves were performed according to established standards23,24.
Rodent tumor models, immunization, T cell depletion. All procedures involving
vertebrate animals were performed under a Duke IACUC-approved protocol.
Homozygous hCD155-tg C57Bl6 mice are maintained as a breeding colony; they
were originally obtained from S. Koike57. 5 × 105 B16F10.9-OVA murine mela-
noma cells were implanted orthotopically in hCD155-tg mice9. AAD-tg C57Bl6
mice (Jackson Labs, strain #004191) express an interspecies hybrid class I MHC
gene, AAD, which contains the α-1 and -2 domains of the human HLA-A2.1 gene
and the α-3 transmembrane and cytoplasmic domains of the mouse H-2Db gene,
under the direction of the human HLA-A2.1 promoter. Heterozygous hCD155-
and AAD(HLA-A2)-tg C57Bl6 mice were obtained by cross breeding hCD155-tg
mice with AAD-tg mice. Murine CT2AAAD_H3.3K27M malignant gliomas were
implanted intracerebrally in hCD155/AAD-tg mice as follows. Mice were anes-
thetized (isofluorane), scalp sterilized (betadine and 70% ethanol) and an incision
was made along the sagittal suture to expose the bregma. A hole was drilled in the
skull near the right coronal suture (2 mm right/0.5 mm anterior to the bregma) and
a 30 G needle was used to inoculate 105 CT2AAAD_H3.3K27M cells in 5 μL
methylcellulose suspension (at 3.33 μL/min) at a depth of 3.6 mm. Mice were
monitored for clinical symptoms and neurological deficits, and weighed daily after
tumor implant; mice were euthanized when they had lost 15% of their max. weight
or when they became symptomatic as defined in our IACUC-approved protocol.
For i.m. vector immunizations, mice 6–12 weeks of age were inoculated in the
gastrocnemius muscle (104–106 pfu). A boost dose was administered on day 14 in
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the contralateral leg (105–107 pfu). For SIINFEKL immunization, 50 μg of poly(I:C)
(high molecular weight VacciGrade; Invivogen) was mixed with 50 μg of SIINFEKL
peptide (Invivogen) for immunization/boost as described above. For H3.3K27M
peptide immunization, 50 μg of RMSAPSTGGV (Peptide 2.0) was emulsified in
Complete Freund’s Adjuvant (Sigma) and administered intraperitoneally. A boost
dose was administered on day 14 with 50 μg of RMSAPSTGGV emulsified in
Incomplete Freund’s Adjuvant (Sigma). For CD8 T cell depletion, anti-CD8
antibody (BioXCell, BE0061) was administered i.p. (250 μg/dose), starting 7 days
before tumor implantation, and continuing every 4 days thereafter.
Immunoblot/immunoprecipitation, flow cytometry, and IHC. Immunoblots and
immunoprecipitation were performed using standardized protocols with the
antibodies listed in Supplementary Table 258. For flow cytometry, cells were washed
with- and resuspended in 100 μL FACs buffer (phosphate-buffered saline, 2% fetal
bovine serum). The cells were Fc-blocked (TruStain, Biolegend), stained (1 h) with
the appropriate antibodies (Supplementary Table 2), washed and resuspended in
250 μL FACs buffer to be analyzed on a BD LSRFortessaX20. Compensation and
data were analyzed using FlowJo. H2Kb-SIINFEKL pentamer (Proimmune)
staining was performed with blood seven days post boost-immunization according
to manufacturer’s protocol. The HLA-A2-RMSAPSTGGV tetramer was synthe-
sized by the NIH Tetramer Core Facility. hCD155_AAD-tg mice were immunized
with vector or peptide and bled one week after boost. Blood was lysed with ACK
Lysing buffer (Gibco, A1049201), washed (FACs buffer), stained with tetramer
(30 min, 20 °C), washed, Fc-blocked (see above), stained with CD8, CD19 and
CD11b antibodies and analyzed as described above. For IHC, lymph nodes were
harvested from euthanized mice, fixed in 4% parafomaldehyde, dehydrated in 70%
ethanol, paraffin-embedded and sectioned (7 μM). Mounted sections were stained
using the Ventana Discovery Ultra platform (Research Immunohistology Lab,
Duke Dept. of Pathology).
ELISA, cytokine bead array, and ELISPOT. We used Ready-Set-Go ELISA kits
(ThermoFisher) for Granzyme B, IFNγ and (human) IL2 ELISAs. Cytokine Bead
Arrays were performed using Biolegend mouse (#740621) and human (#740390)
antivirus LEGENDplex kits. Mouse skeletal muscle tissues were minced in 500 μL
of DMEM medium, centrifuged, and the resulting supernatants were used for
LEGENDplex analyses. For ELISPOTs, plates (Millipore, MSIPS4W10) were pre-
activated with 35% ethanol, washed 6 times with PBS, and coated with 10 μg/mL of
antibody [IFNγ; AN-18 (Mabtech)] (12 h, 4 °C). Plates were blocked with R10
medium [RPMI, 10% FBS, non-essential amino acids, 1 × 2-mercaptoethanol
(Gibco 21985023)] (2 h, 37 °C) prior to splenocyte addition. Spleens were processed
into single cell suspension, red blood cells lysed using ACK Lysing buffer, and
splenocytes washed with R10 medium. Cells were plated at a density of 5 × 105/well
in 100 μL of R10 in triplicate, and remained unstimulated or stimulated with 10 μg/
mL of peptide [OVA257–264 (Invivogen); myelin-oligodendrocyte glycoprotein
(MOG35–55) (Sigma)]; 4 μg/mL Concanavalin A (Sigma) and incubated (24 h,
37 °C). After incubation, the plates were washed with PBS/0.05% Tween, incubated
with biotin-labeled anti-mouse IFNγ [R4-6A2 (Mabtech); 1 μg/mL] (2 h, 37 °C),
washed, incubated with Avidin Peroxidase Complex (VectaStain, 1 h) and devel-
oped with AEC ELISpot substrate. All ELISPOT assays were evaluated externally by
Zellnet Consulting.
Cell lines, primary cultures, co-culture assays. Cell lines: We used HeLa R19-
and HEK293 cells for virus propagation and one-step growth curve assays28.
B16F10.9 murine melanoma cells were obtained from ATCC; derivation of
B16F10.9-OVA was described elsewhere9. CT2A cells were kindly provided by Dr.
P. Fecci (Duke Univ.); the CT2A stock was validated by whole exome genome
sequencing. CT2A_AADH3.3K27M cells were derived by transfecting CT2A cells
with linearized AAD (Addgene #14906)59 cDNA, followed by transduction with
lentivirus expressing H3.3K27M (a gift from Dr. H. Yan, Duke Univ.).
CT2A_AADH3.3K27M cells were sorted to select for HLA-A2+ cells and H3.3K27M-
expressing cells were selected with hygromycin (2 weeks at 100μg/mL). DIPG 36
cells were generously provided by Dr. M. Monje (Stanford Univ.). The Jurkat T cell
line (J76CD8+ TCR+) was generated by lentiviral transfection of J76CD8+ cells60
with the cDNA of a TCR with high affinity for the H3.3K27M epitope
(RMSAPSTGGV) isolated from PBMCs of an HLA-A2+, H3.3(K27M)-mutated
DIPG patient15. Primary cultures: Mouse bone marrow-derived dendritic cells
(BMDCs) were generated from bone marrow cells extracted from femurs and tibias
dissected from hCD155-tg C57Bl6 mice. Bones were flushed out bone marrow, red
blood cell lysed with ACK Lysing buffer and cells were washed with R10 medium.
For GMCSF-BMDCs: cells were counted and plated at 106 cells/mL, supplemented
with IL-4 (10 ng/mL; Sigma, I1020) and GMCSF (20 ng/mL; Sigma, G0282). On
day 3, fresh R10 medium with IL-4/GMCSF was added. On day 7, the loosely
adherent cells were harvested and re-plated at 106 cells/mL for subsequent
experiments. For FLT3L-BMDCs: cells were plated at 2.56 cells/mL in R10 medium
supplemented with 300 ng/mL FLT3L (ThermoFisher, PHC9415) for 9 days33. All
BMDC preparations were tested for CD11c expression by flow cytometry. Human
monocyte-derived DCs (human DCs) were derived from PBMCs obtained
from Stem Cell Technologies (#70025) briefly, monocytes were cultured with
GMCSF/IL4 for 6 days in AIMV medium9,61. OT-I CD8 T cell/BMDC co-culture:
105 OT-I CD8 T cells (isolated from OT-I transgenic mouse spleen (Jackson
Laboratories #003831) using the Biolegend CD8 T cell isolation kit #480008) and
105 GMCSF-BMDCs (with appropriate treatment) were cocultured for 3 days in a
96-well U-bottom plate. Supernatant was harvested and tested for Granzyme-B and
IFN-γ by ELISA. J76CD8+ TCR+ T cell/hDC co-culture: J76CD8+ TCR+ cells
were sorted using CD8 and Tetramer+ (BD DiVa Sorter, Duke Cancer Institute
Flow Cytometry Core) and co-cultured with hDCs (HLA-A2+) treated with either
virus, peptide or mock were cocultured with J76 cells (48 h) in U-bottom 96 well
plate. In co-culture experiments with peptide stimulation, 12-O-tetra-
decanoylphorbol-13-acetate (TPA; Sigma Aldrich) was added (10 ng/mL). IL-2
ELISA was performed with supernatant after 48 h.
Statistical analysis. Statistical analyses were preformed using GraphPad Prism.
Error bars represent Standard Error of the Mean (SEM). Significance was deter-
mine dusing two-tailed Student’s t test when comparing 2 groups; for multiple
groups, an ANalysis Of VAriance (ANOVA) was first performed followed by the
appropriate post hoc test as described in the figure legends. The number of
independent replicates (n) and number of times experiments were repeated are
indicated in the figure legends.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting our findings are included within the Manuscript and Supplement.
The source data underlying all figures in this manuscript are provided as Source
Data files.
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